Drug Profile
LY 2623091
Alternative Names: LY-2623091Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Mineralocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Essential hypertension; Renal failure
Most Recent Events
- 01 Apr 2015 Eli Lilly completes a phase I pharmacokinetics study in Healthy volunteers in USA (NCT02300259)
- 01 Mar 2015 Eli Lilly completes a phase II trial in Essential hypertension in Canada, Puerto Rico and USA (NCT02194465)
- 01 Nov 2014 Eli Lilly initiates enrolment in a phase I pharmacokinetics study in Healthy volunteers in USA (NCT02300259)